With buyout on Horizon, Amgen and Sanofi eye cash plays for rare disease drug maker

The battle to absorb rare disease drug maker Horizon Therapeutics will be waged with cash.

That was the message from interested bidders Sanofi and Amgen, at least, which issued separate statements this week on the heels of Horizon’s confirmation that buyout interest is booming.